Get the Stockscreener App
1.26
5.88%
0.07
Pre-market:
1.22
-0.04
-3.17%
Abvc Biopharma Inc stock is traded at $1.26, with a volume of 92,308.
It is up +5.88% in the last 24 hours and up +15.60% over the past month.
ABVC BioPharma Inc is a clinical stage biopharmaceutical company focused on development of new drugs and medical devices, all of which are derived from plants. It currently has six drugs and three medical devices in development. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes. Its products include: Vitargus - ABV-1701, ABV-2001, ABV-2002, MDD ABV-1504, ADHD ABV-1505, ADHD ABV-1601, ABV-1501, ABV-1702, and ABV-1703.
See More
Previous Close:
$1.19
Open:
$1.19
24h Volume:
92,308
Relative Volume:
0.85
Market Cap:
$32.76M
Revenue:
$2,000
Net Income/Loss:
$-9.12M
P/E Ratio:
-3.2366
EPS:
-0.3893
Net Cash Flow:
$-3.35M
1W Performance:
-5.97%
1M Performance:
+15.60%
6M Performance:
-37.93%
1Y Performance:
-28.81%
1-Day Range:
$1.19
$1.29
1-Week Range:
$1.19
$1.38
52-Week Range:
$0.8801
$5.48
Abvc Biopharma Inc Stock (ABVC) Company Profile
Name
Abvc Biopharma Inc
Sector
Industry
Phone
510-668-0881
Address
44370 OLD WARM SPRINGS BLVD., FREMONT
Compare ABVC vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABVC
Abvc Biopharma Inc
|
1.26 | 32.76M | 2,000 | -9.12M | -3.35M | -0.3893 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Abvc Biopharma Inc Stock (ABVC) Latest News
ABVC BioPharma Inc. (ABVC) Surges 7.39% — Testing Key Resistance at $1.34Relative Volume - newsline.com
ABVC Q1 2025 Earnings: Net Loss of -$0.06 Per Share Reflects Pre‑Revenue Development Stage; Stock Declines 9.2% - newsline.com
ABVC BioPharma Inc. (ABVC) Edges Higher as Shares Test Resistance Near $1.41Ichimoku Kumo Break - newsline.com
ABVC BioPharma Inc. (ABVC) Q1 2025 Earnings: Narrowing Losses Amid Clinical ProgressRevenue Recognition Risk - newsline.com
ABVC BioPharma Slips 7.6%: Support at $1.26 in Focus After Volatile SessionSeasonality Effect - newsline.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
ABVC BioPharma Surges 6.64%: Shares Break Above Key Support as Momentum BuildsUp Down Volume - newsline.com
ABVC PE Ratio & Valuation, Is ABVC Overvalued - Intellectia AI
ABVC Q1 2025 Earnings: Pre‑Revenue Biotech Reports Net Loss as Pipeline Development Continues - newsline.com
ABVC BioPharma Inc. (ABVC) Q1 2025 Earnings: Modest Loss Reported Amid Ongoing Clinical Development - The Legal Advocate
ABVC BioPharma Creeps Higher, Testing Resistance at $1.48Bullish Percent Index - The Legal Advocate
ABVC BioPharma Consolidates at $1.39 as Support and Resistance Levels NarrowPCR Divergence - The Legal Advocate
ABVC BioPharma Surges 13%: Key Levels and Potential ScenariosShort Term Trading Ideas - thelegaladvocate.com
ABVC BioPharma Inc. (ABVC) Surges 9.65% in Active Trading as Biotech Investor Sentiment ImprovesMcClellan Summation - The Legal Advocate
ABVC BioPharma Inc. (ABVC) Edges Higher After Recent Pullback, Testing Key Resistance LevelIV Expansion Alert - Newser
ABVC BioPharma Inc. Q1 2025 Earnings: Narrowed Loss Highlights Continued Pipeline ProgressBuyback Announcement Report - The Legal Advocate
ABVC BioPharma Inc. (ABVC) Holds Steady Above Support After Modest GainSocial Flow Trades - Newser
ABVC BioPharma Reports Continued Losses and No Revenue in Q1 2026, Raising Doubts About Financial Stability - Minichart
Why Is ABVC BioPharma, Inc. (ABVC) Stock Up Today? - Meyka
Why Is ABVC BioPharma, Inc. (ABVC) Stock Down Today? - Meyka
ABVC BioPharma, Inc. 1Q 2026: Revenue ($1.55M), Net income ($1.56M), EPS ($0.06) — 10-Q Summary - TradingView
ABVC: Q1 2026 saw a $1.69M net loss, no revenue, and a $4.74M working capital deficit - TradingView
ABVC BioPharma (NASDAQ: ABVC) posts Q1 loss and going concern warning - Stock Titan
ABVC BioPharma Delays Quarterly SEC Filing - TipRanks
ABVC (ABVC) files Form 12b-25: late 10-Q for March 31, 2026 - Stock Titan
TradingKey - TradingKey
How sustainable is BioPharma (ABVC) profit margins? (Institutional Selling) 2026-05-08MACD Signals - newser.com
ABVC BioPharma drops 6.14% after Q1 2025 quarterly earnings post a 0.06 dollar per share loss with no prior analyst estimates.Management Guidance Update - newsline.com
ABVC BioPharma Inc. posts $0.06 EPS loss, no published estimatesGuidance Accuracy Score - newsline.com
BioPharma (ABVC) Stock: Why Industry Position (Pulls Back) 2026-04-15Breakout Signals - Cổng thông tin điện tử tỉnh Lào Cai
ABVC Options Volatility — NASDAQ:ABVC - TradingView
ABVC Options Chain — NASDAQ:ABVC - TradingView
Published on: 2026-04-10 10:41:09 - baoquankhu1.vn
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Is BioPharma (ABVC) Stock Growing Now | Price at $1.33, Up 20.91%Fibonacci Retracement - newsline.com
ABVC Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
ABVC BioPharma Shareholders Back Board, Equity Plan Changes - TipRanks
ABVC BioPharma shareholders approve director slate and equity plan at annual meeting By Investing.com - Investing.com South Africa
ABVC BioPharma shareholders approve director slate and equity plan at annual meeting - Investing.com
ABVC BioPharma (ABVC) investors re-elect board and approve 2026 plan - stocktitan.net
ABVC BioPharma | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filingmoomoo - Moomoo
Aug Weekly: What is ABVC BioPharma Incs market positionEarnings Summary Report & Precise Buy Zone Identification - baoquankhu1.vn
Bull Run: Is ABVC BioPharma Inc part of any major indexWeekly Stock Analysis & Fast Exit Strategy with Risk Control - baoquankhu1.vn
Aug Breakouts: Can ABVC BioPharma Inc benefit from deglobalizationTrade Analysis Report & Precise Swing Trade Entry Alerts - baoquankhu1.vn
ABVC BioPharma (ABVC) plans 2026 virtual meeting, director votes and equity plan increase - Stock Titan
ABVC SEC FilingsAbvc Biopharma Inc 10-K, 10-Q, 8-K Forms - Stock Titan
ABVC BioPharma Reports 179% Asset Growth in 2025, Shifts Toward Hybrid Business Model - citybuzz -
According to the latest filing submitted to the U.S. Securities and Exchange Commission (SEC), ABVC BioPharma, Inc. has identified significant deficiencies in its internal control over financial reporting for the fiscal year 2025. - Bitget
ABVC BioPharma Reports 2025 Form 10-K - Yahoo Finance
ABVC BioPharmaquarterly period ended September, 2025 financial statements should not be relied upon - marketscreener.com
Abvc Biopharma Inc Stock (ABVC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):